Clinical Development

Building the future clinical pathway for objective recovery monitoring

RetinaTek is advancing task-evoked neurocognitive measurement through research deployments today, a planned RT-Focus cognitive performance product, and future regulated clinical-development pathways for adult and pediatric concussion/mTBI.

The clinical challenge after concussion is not only whether an injury occurred. It is whether the person is recovering as expected. RetinaTek's future clinical-development strategy is focused on objective, repeatable measurement that may support longitudinal decision-making after appropriate validation and regulatory clearance.

Review the evidence Contact the team
A patient completes a supervised headset-based assessment while a clinician monitors nearby.

Three pathways, one measurement platform

RetinaTek separates current research use, planned commercial cognitive-performance assessment, and future regulated clinical claims. Each pathway has a different purpose, evidence requirement, and claims boundary.

1

Research and clinical-development deployments now

RetinaTek can support research and clinical-development deployments today, including studies focused on objective neurocognitive endpoints, longitudinal research protocols, usability, workflow feasibility, and validation of task-evoked multimodal metrics.

Use cases

  • Academic and clinical research
  • Observational concussion/mTBI research studies
  • Rehabilitation and recovery-tracking research protocols
  • Endpoint development for clinical trials
  • Usability, workflow, and data-quality studies
2

RT-Focus commercial development

RT-Focus is RetinaTek's first planned commercial product for supervised cognitive performance assessment in premium clinical settings. RetinaTek is engaging FDA through the Q-submission process to confirm the appropriate regulatory pathway. RT-Focus is designed to create a practical, repeatable brain-performance baseline while maintaining clear separation from disease-diagnostic or disease-monitoring claims.

Use cases

  • Executive medicine
  • Concierge primary care
  • Longevity and preventive health clinics
  • Cognitive performance baselining
  • Repeatable member-facing brain-performance reporting
3

Future regulated concussion/mTBI indications

RetinaTek is pursuing NIH applications and partner-supported validation programs for adult and pediatric concussion and mild TBI, with an emphasis on future objective recovery-monitoring, treatment-response tracking, and regulated clinical claims after appropriate validation and clearance.

Use cases after appropriate validation and clearance

  • Future recovery-trajectory measurement
  • Treatment-response tracking
  • Return-to-activity decision support
  • Identification of patients not recovering as expected
  • Adjunctive clinical decision support

The larger clinical need is recovery trajectory

Diagnosis matters, but it is only the starting point. After concussion or mild TBI, clinicians and patients face a more difficult question: is recovery progressing as expected?

Symptoms can be subjective. Standard imaging is often normal. Brief cognitive screens may miss subtle deficits or fail to show whether a patient is improving, plateauing, or worsening over time. Clinical decisions often depend on episodic visits and incomplete information.

RETINA's future clinical-development focus is longitudinal: brief, repeatable, task-standardized measurement that may help characterize recovery trajectory after appropriate validation and clearance.

Recovery question

Is the patient improving?

Objective repeat testing may help show whether performance is moving in the expected direction.

Recovery question

Is recovery plateauing?

Longitudinal measurement may help identify patients whose recovery trajectory is not progressing as expected.

Recovery question

Is treatment working?

Repeatable cognitive-performance measures may support treatment-response tracking in future validated use cases after appropriate validation and clearance.

Recovery question

Is escalation warranted?

Objective performance trends may help inform when additional evaluation, specialty care, imaging, or biomarkers are most appropriate.

Built for repeat measurement under controlled cognitive load

RETINA is brief, task-standardized, and designed to measure performance under controlled cognitive demand. That makes the platform well suited to tracking change over time rather than producing only a one-time snapshot.

Longitudinal tracking

Brief administration

Designed for low-burden, repeatable testing in research and supervised clinical workflows.

Longitudinal tracking

Standardized task context

The same cognitive demands can be presented consistently across visits.

Longitudinal tracking

Multimodal signals

Eye movements, pupil dynamics, manual responses, and task timing provide complementary views of performance.

Longitudinal tracking

Objective change over time

Longitudinal testing can help characterize whether performance is improving, stable, or declining.

Longitudinal tracking

Data-quality checks

Automated quality checks help determine whether results are usable and interpretable.

Longitudinal tracking

Scalable deployment

Headset-based administration supports use outside specialized neuropsychology or imaging environments.

Potential value: better allocation of care

After validation and regulatory clearance for the intended use, objective recovery tracking may help clinicians allocate care more efficiently. Patients whose performance trajectory is not improving as expected may warrant additional evaluation, specialty referral, imaging, biomarkers, or intensified treatment. Patients whose recovery trajectory appears to be progressing appropriately may avoid unnecessary escalation.

RETINA is not intended to replace clinician judgment, imaging, blood biomarkers, or specialist evaluation. The goal is to provide a repeatable functional measurement layer that complements those tools and helps clinicians make better longitudinal decisions.

Potential value

Focus specialty resources

After validation and clearance for the intended use, help identify patients whose recovery trajectory suggests elevated need.

Potential value

Inform treatment intensity

After validation and clearance for the intended use, support decisions about whether care should continue, intensify, or step down.

Potential value

Support return-to-activity decisions

Provide objective recovery information that may complement clinical judgment.

Potential value

Reduce unnecessary escalation

Potentially avoid additional high-burden evaluation when recovery is proceeding appropriately.

Potential value

Complement biomarkers and imaging

Provide repeatable functional performance data alongside biological and structural tools.

Clinical-development roadmap

RetinaTek's roadmap is staged to create value while maintaining clear claims boundaries and building the evidence required for future regulated indications.

  1. Current research deployments

    Support research and clinical-development studies using task-evoked multimodal neurocognitive endpoints.

  2. NIH and partner-funded validation planning

    Pursue NIH applications, funding, and partnerships for adult and pediatric concussion/mTBI validation programs.

  3. Product and software lock

    Define the device/software configuration, administration workflow, scoring outputs, documentation, and data-handling processes for future clinical studies.

  4. Quality-system readiness

    Advance documentation, usability, cybersecurity, risk management, data integrity, and quality controls appropriate for regulated development.

  5. FDA pre-submission engagement

    Engage FDA through the Q-submission process to confirm the appropriate regulatory pathway and align on intended use, claims, endpoints, comparator strategy, study design, and submission pathway.

  6. Prospective adult and pediatric validation

    Evaluate performance in intended-use populations with pre-specified endpoints, repeatability, usability, safety, and data-quality measures.

  7. Initial regulated indication and expansion

    Pursue a narrowly defined first clinical claim, then expand into adjacent monitoring use cases after evidence and clearance support additional indications.

What future validation must establish

Future regulated claims require more than promising science. RetinaTek's clinical-development work must demonstrate that the platform is repeatable, usable, interpretable, and clinically meaningful in the intended-use population.

Intended-use population

Adult and pediatric subgroup considerations

Repeatability and reliability

Reliable change over time

Sensitivity to recovery trajectory

Relationship to clinician assessment and accepted benchmarks

Treatment-response tracking potential

Usability and tolerability

Data quality and interpretability

Safety and risk controls

Workflow feasibility

Clear claims and labeling

Clear claims boundaries

Current positioning

  • Research and clinical-development deployments are available now.
  • RT-Focus is a planned supervised cognitive performance assessment for premium clinical settings, with FDA pathway discussions ongoing through the Q-submission process.
  • RETINA is a task-evoked neurocognitive measurement platform.
  • Current work focuses on objective, repeatable measurement under controlled cognitive load.
  • RetinaTek is pursuing validation pathways for future adult and pediatric concussion/mTBI indications.

Not claimed today

  • RETINA is not currently FDA-cleared, FDA-approved, or authorized for diagnostic use.
  • RT-Focus should not be presented as a diagnostic, screening, or disease-monitoring product.
  • Current deployments do not replace clinician judgment.
  • RETINA does not replace imaging, blood biomarkers, emergency assessment, or specialist evaluation.
  • Disease-specific diagnostic or monitoring claims require appropriate validation and regulatory clearance.

RetinaTek's goal is to provide an objective functional measurement layer that complements existing tools and supports better longitudinal decisions.

Regulatory status

RETINA is an in-development neurocognitive measurement platform. RT-Focus is a planned supervised cognitive performance assessment, and RetinaTek is engaging FDA through the Q-submission process to confirm the appropriate regulatory pathway. Current public materials do not claim that RETINA or RT-Focus is FDA-cleared, FDA-approved, or authorized for diagnostic use. Disease-specific diagnostic or monitoring claims require appropriate validation and regulatory clearance.

Interested in clinical-development collaboration?

RetinaTek is building relationships with clinicians, researchers, health systems, rehabilitation providers, and strategic partners interested in objective neurocognitive measurement, future recovery-monitoring pathways after appropriate validation and clearance, and future regulated clinical applications.

Contact the team Review the evidence